Calif. biotech gets $13.5M funding boost

05/7/2013 | American City Business Journals

NGM Biopharmaceuticals secured almost $13.5 million in an equity offering targeted at $50 million, a securities filing showed. Rather than betting on a single drug, NGM is using a basic-science approach to uncover how genes, hormones and receptors regulate diabetes, obesity and other cardiometabolic disorders. The company hopes to develop a treatment that mimics the benefits of gastric bypass surgery, which has been shown to improve type 2 diabetes outcomes even before weight loss begins.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL